Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner

Vera Therapeutics announced that William Turner, current Chief Regulatory Officer, will retire and transition to Strategic Advisor role in Q3 2026. Nancy Boman, M.D., Ph.D., with over 25 years of regulatory affairs experience, will succeed him. The transition follows the recent accelerated FDA approval of TRUTAKNA (atacicept-vymj), the company's first therapy for IgA nephropathy.